Trump says Iran war "close to over" amid hopes for more negotiations
Investing.com -- STAAR Surgical Company (NASDAQ:STAA) rose 18% in after-hours trading Wednesday after announcing preliminary first quarter net sales that significantly exceeded Wall Street expectations.
The vision correction company said net sales for the first quarter ended April 3, 2026 are expected to exceed $90 million, compared to analyst estimates of $67.2 million. The figure represents more than double the $42.6 million in net sales reported in the first quarter of 2025.
China, the company’s largest market, accounted for the majority of the sales increase, while the Americas region posted continued double-digit growth. STAAR said the higher net sales, combined with an improved cost structure, are expected to drive meaningful improvement in adjusted EBITDA for the quarter.
The company noted that first quarter 2025 sales were impacted as it shipped minimal quantities of EVO ICLs to China while distributors worked through excess inventory. As of the end of the first quarter of 2026, distributor inventory appears to be within the company’s targeted range.
However, net sales in the Middle East and some parts of the EMEA and APAC regions were negatively affected by geopolitical and macroeconomic challenges, resulting in a decline in those areas. The company cautioned that sales growth could continue to be adversely affected if these conditions persist.
"These results deliver on two of the three core objectives outlined in our Shareholder Letter earlier this year—Revenue Growth and Profit Expansion—and though early in the year, are indicators of the overall good health of our business," said Deborah Andrews, Interim Co-CEO and CFO.
STAAR said it continues to provide no forward revenue or earnings guidance and expects to report full first quarter financial results in early May. The preliminary figures are unaudited and subject to adjustment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.